STM publisher Elsevier, Netherlands, has announced that Karo Bio, a developer of innovative drugs for large medical needs, has started to use Reaxys and Reaxys Medicinal Chemistry. Karo Bio has chosen the solutions to support its chemists in their research and development objectives, ensuring they have quick and easy access to state of the art chemistry information.
Reaxys, with its recent expansion of chemistry data and capabilities now encompassing content of over 16,000 periodicals, is recognised by users as having the deepest and richest fact-base of experimentally measured chemistry data. Reaxys Medicinal Chemistry offers access to data from a vast repository of peer-reviewed journal articles and patents and is interoperable with Reaxys.
Adding this content to Karo Bio's information sources means that chemists will have readily available access to relevant information. That, coupled with the flexibility of the search function and the way results are presented, will enable chemists to more quickly identify and prioritise viable compounds, helping reduce the time it takes to bring innovative drugs to market.
Reaxys and Reaxys Medicinal Chemistry are part of Elsevier Life Science Solutions, a suite of interoperable, domain-specific, decision support tools which span the discovery and development workflow; including ScienceDirect, Scopus, TargetInsights, Pathway Studio, PharmaPendium, QUOSA and Embase.
